BioSpace News Archive

PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy.

Boston Pharmaceuticals today announced additional Phase 2 data supporting the low risk of immunogenicity and positive clinical effects associated with BOS-580, the company’s investigational, long-acting fibroblast growth factor 21 (FGF21) analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH).

Twist Bioscience Corporation today announced the appointment of Adam Laponis as chief financial officer.

MAIA Biotechnology, Inc. today announced its participation in the Biotech Showcase ™ 2024 investor conference being held January 8-10, 2024, in San Francisco, California.

Nimbus Therapeutics , LLC announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.

Journey Medical Corporation today announced that the Company has submitted a New Drug Application (“NDA”) to the FDA seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd.

NurExone Biologic Inc. is pleased to announce that it has closed a non-brokered private placement (the “ Private Placement ”).

Biocare Medical, a leader in fully open automated instrumentation, announces a collaboration with Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology.

Kriya Therapeutics, Inc., (Kriya) today announced its gene therapy program for thyroid eye disease (TED), a debilitating autoimmune condition resulting in proptosis and diplopia, medical terms describing bulging of the eyes and double vision respectively, due to inflammation of the muscles and fat tissue behind the eye.

Avenue Therapeutics, Inc. today announced the entry into warrant exercise agreements with existing accredited investors for the immediate exercise of certain outstanding warrants to purchase an aggregate of 16.5 million shares of the Company’s common stock.